Table 1.
Patient characteristics (n=284)
| Patient characteristics | ALRI
|
p-values | |
|---|---|---|---|
| <14
|
≥14
|
||
| n (%) | n (%) | ||
| Median age, years (range) | 66 (34–83) | 65 (33–81) | 0.771 |
| Gender | 0.904 | ||
| Male | 86 (60.6) | 84 (59.2) | |
| Female | 56 (39.4) | 58 (40.8) | |
| Performance status ECOG | 0.005 | ||
| 0 | 123 (86.6) | 103 (72.5) | |
| 1–2 | 19 (13.4) | 39 (27.5) | |
| Tumor localization | 0.893 | ||
| Rectum | 37 (26.1) | 38 (26.8) | |
| Colon | 105 (73.9) | 104 (73.2) | |
| Stage at diagnosis | 0.646 | ||
| I–III | 35 (25.9) | 31 (22.8) | |
| IV | 100 (74.1) | 105 (77.2) | |
| CT regimen | 0.028 | ||
| FOLFOX4 | 97 (68.3) | 78 (54.9) | |
| FOLFIRI | 45 (31.7) | 64 (45.1) | |
| KRAS statusa | 0.387 | ||
| Wild type | 95 (66.9) | 87 (61.3) | |
| Mutated | 47 (33.1) | 55 (38.7) | |
| ITACa treatment | 0.812 | ||
| CT+B | 67 (47.2) | 70 (49.3) | |
| CT | 75 (52.8) | 72 (50.7) | |
Note:
a
Mandatory as consequence of amendment no 1 of May 3, 2009.
Abbreviations: ALRI, aspartate aminotransferase-lymphocyte ratio index; B, bevaci zumab; CT, chemotherapy; ECOG, Eastern Cooperative Oncology Group; ITACa, Italian Trial in Advanced Colorectal Cancer; n, number.